NCT04552886View on ClinicalTrials.gov

Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions

Glioblastoma

Interventions

BIOLOGICAL

TH-1 Dendritic Cell Immunotherapy

Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation.

Trial Locations (2)

77030

Memorial Hermann- Texas Medical Center, Houston

08103

Cooper University Hospital, Camden

All Listed Sponsors

collaborator

Baylor College of Medicine

OTHER

collaborator

Philadelphia College of Osteopathic Medicine

OTHER

lead

The Cooper Health System

OTHER

NCT04552886 - Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | Biotech Hunter | Biotech Hunter